Among these, Pemigatinib (BGJ398) has been approved for use in ICC patients presenting with FGFR2 fusion, while Tibsovo has received approval for treating ICC patients carrying an IDH1 mutation [38]. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.